Voyager Therapeutics Inc (NASDAQ:VYGR) insider Bernard Ravina sold 3,630 shares of the stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $16.40, for a total value of $59,532.00. Following the completion of the sale, the insider now directly owns 7,353 shares of the company’s stock, valued at approximately $120,589.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Bernard Ravina also recently made the following trade(s):
- On Monday, December 11th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The shares were sold at an average price of $13.63, for a total value of $74,828.70.
- On Friday, November 10th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The shares were sold at an average price of $13.26, for a total value of $72,797.40.
Voyager Therapeutics Inc (VYGR) opened at $18.76 on Monday. Voyager Therapeutics Inc has a 12-month low of $8.10 and a 12-month high of $25.99. The company has a market capitalization of $590.00, a price-to-earnings ratio of -6.61 and a beta of 4.04.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.17). Voyager Therapeutics had a negative return on equity of 65.50% and a negative net margin of 1,195.63%. equities analysts forecast that Voyager Therapeutics Inc will post -2.99 earnings per share for the current fiscal year.
A number of equities research analysts recently weighed in on VYGR shares. Raymond James Financial started coverage on Voyager Therapeutics in a research note on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price target on the stock. Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Stifel Nicolaus restated a “buy” rating and issued a $31.00 price target (up previously from $20.00) on shares of Voyager Therapeutics in a research note on Monday, October 23rd. Canaccord Genuity initiated coverage on Voyager Therapeutics in a research note on Friday, October 27th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Robert W. Baird initiated coverage on Voyager Therapeutics in a research report on Monday, October 30th. They set an “outperform” rating and a $31.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. Voyager Therapeutics presently has an average rating of “Buy” and a consensus price target of $26.90.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. increased its position in shares of Voyager Therapeutics by 57.7% in the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after purchasing an additional 4,343 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in Voyager Therapeutics in the second quarter valued at about $143,000. Rhumbline Advisers boosted its stake in Voyager Therapeutics by 34.7% in the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after buying an additional 4,144 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after buying an additional 1,399 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in Voyager Therapeutics by 24.7% in the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after buying an additional 5,081 shares in the last quarter. Institutional investors own 36.10% of the company’s stock.
WARNING: “Bernard Ravina Sells 3,630 Shares of Voyager Therapeutics Inc (VYGR) Stock” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/05/voyager-therapeutics-inc-vygr-insider-bernard-ravina-sells-3630-shares.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.